← Leaderboards
Jack A Elias
Yale University
$29,308,180
Attributed
$33,217,892
Total exposure
16
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$47,410,660 · 18
By mechanism
R01$13,440,567 · 8
P01$12,810,227 · 3
T32$6,084,471 · 1
P50$4,679,791 · 3
UH3$4,532,610 · 1
UH2$3,286,814 · 1
Top collaborators
- Geoffrey L Chupp5 shared
Most similar at Yale University
Same institution · by research overlap
- Jordan S Pober$30,894,969
- Tao Zheng$2,822,756
- Zhou Zhu$4,616,353
- Anton M Bennett$24,651,394
- Chun Geun Lee$5,468,680
Others in their field
Top investigators on “Cytokine”
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$83,965,880
- David Heimbrook · Leidos Biomedical Research, Inc.$56,453,265
- Fulton T Crews · University Of North Carolina Chapel Hill$36,249,590
- Marianne Ward · Duke University$34,872,957
- Joren C Madsen · Massachusetts General Hospital$33,058,731
- Barton F Haynes · Duke University$29,068,807
Research focus
CytokineInflammationLungPathway InteractionsResponseTissuesAsthmaApoptosisMediatingReceptorLaboratory MousePathogenesisGenesPlayEpithelial CellsBiologyInjuryHelper T LymphocyteProteinsChitinaseMacrophageEpithelialRepairedGenetically Modified Animals
Grant awards (76)
Differential Roles of Chi3l1 and its receptors in COPD and IPF$337,031
P01 · FY2025 · HL · contact PI
Differential Roles of Chi3l1 and its receptors in COPD and IPF$324,337
P01 · FY2024 · HL · contact PI
Differential Roles of Chi3l1 and its receptors in COPD and IPF$332,669
P01 · FY2023 · HL · contact PI
Differential Roles of Chi3l1 and its receptors in COPD and IPF$332,479
P01 · FY2022 · HL · contact PI
Differential Roles of Chi3l1 and its receptors in COPD and IPF$379,824
P01 · FY2021 · HL · contact PI
Pre-Clinical Development of a Novel Anti-YKL-40 Biologic to Treat Severe Asthma$1,628,646
UH3 · FY2018 · HL
Pre-Clinical Development of a Novel Anti-YKL-40 Biologic to Treat Severe Asthma$1,645,902
UH3 · FY2017 · HL
Pre-Clinical Development of a Novel Anti-YKL-40 Biologic to Treat Severe Asthma$1,258,062
UH3 · FY2016 · HL
Pre-Clinical Development of a Novel Anti-YKL-40 Biologic to Treat Severe Asthma$1,623,663
UH2 · FY2015 · HL
Pre-Clinical Development of a Novel Anti-YKL-40 Biologic to Treat Severe Asthma$1,663,151
UH2 · FY2014 · HL
YKL-40 in Idiopathic Pulmonary Fibrosis and Kidney Transplantation$633,818
U01 · FY2014 · HL · contact PI
YKL-40 in Idiopathic Pulmonary Fibrosis and Kidney Transplantation$622,247
U01 · FY2013 · HL · contact PI
BRP-39/YKL-40 in Th2 Inflammation and Asthma$233,138
R01 · FY2013 · HL · contact PI
BRP-39/YKL-40 in Th2 Inflammation and Asthma$156,813
R01 · FY2013 · HL · contact PI
YKL-40 in Idiopathic Pulmonary Fibrosis and Kidney Transplantation$658,115
U01 · FY2012 · HL · contact PI
Training in Respiratory Biology and Pathobiology$455,312
T32 · FY2012 · HL · contact PI
Cigarette Smoke, RIG-like Helicases and Alveolar Remodeling$409,613
R01 · FY2012 · HL · contact PI
BRP-39/YKL-40 in Th2 Inflammation and Asthma$409,613
R01 · FY2012 · HL · contact PI
YKL-40 in Idiopathic Pulmonary Fibrosis and Kidney Transplantation$662,000
U01 · FY2011 · HL · contact PI
Training in Respiratory Biology and Pathobiology$597,458
T32 · FY2011 · HL · contact PI
Cigarette Smoke, RIG-like Helicases and Alveolar Remodeling$413,750
R01 · FY2011 · HL · contact PI
BRP-39/YKL-40 in Th2 Inflammation and Asthma$413,750
R01 · FY2011 · HL · contact PI
Training in Respiratory Biology and Pathobiology$588,645
T32 · FY2010 · HL · contact PI
Cigarette Smoke, RIG-like Helicases and Alveolar Remodeling$413,750
R01 · FY2010 · HL · contact PI
BRP-39/YKL-40 in Th2 Inflammation and Asthma$413,750
R01 · FY2010 · HL · contact PI
Cigarette Smoke, RIG-like Helicases and Alveolar Remodeling$413,750
R01 · FY2009 · HL · contact PI
Training in Respiratory Biology and Pathobiology$409,897
T32 · FY2009 · HL · contact PI
Training in Respiratory Biology and Pathobiology$601,011
T32 · FY2008 · HL · contact PI
Preotease/Cathepsin-Mediated Apoptosis in COPD$387,569
R01 · FY2008 · HL · contact PI
VEGF in Th2 Inflammation and Asthma$387,569
R01 · FY2008 · HL · contact PI
AMCase and BRP-39 in Th2 Inflammation and Asthma$387,569
R01 · FY2008 · HL · contact PI
Training in Respiratory Biology and Pathobiology$601,011
T32 · FY2007 · HL · contact PI
VEGF in Th2 Inflammation and Asthma$387,569
R01 · FY2007 · HL · contact PI
Preotease/Cathepsin-Mediated Apoptosis in COPD$387,569
R01 · FY2007 · HL · contact PI
Transgenic Modeling of TGF-Beta in the Lung$387,569
R01 · FY2007 · HL · contact PI
AMCase and BRP-39 in Th2 Inflammation and Asthma$387,569
R01 · FY2007 · HL · contact PI
Initiation and Effector Mechanisms in Lung Th2 Immunity$2,150,591
P01 · FY2006 · HL · contact PI
Training in Respiratory Biology and Pathobiology$601,011
T32 · FY2006 · HL · contact PI
AMCase and BRP-39 in Th2 Inflammation and Asthma$399,144
R01 · FY2006 · HL · contact PI
Transgenic Modeling of TGF-Beta in the Lung$399,144
R01 · FY2006 · HL · contact PI
Preotease/Cathepsin-Mediated Apoptosis in COPD$399,144
R01 · FY2006 · HL · contact PI
VEGF in Th2 Inflammation and Asthma$399,144
R01 · FY2006 · HL · contact PI
Mechanisms of IL-13 induced inflammation and fibrosis$307,227
P01 · FY2006 · HL · contact PI
Initiation and Effector Mechanisms in Lung Th2 Immunity$2,091,444
P01 · FY2005 · HL
Training in Respiratory Biology and Pathobiology$570,458
T32 · FY2005 · HL
Transgenic Modeling of TGF-Beta in the Lung$408,750
R01 · FY2005 · HL
Preotease/Cathepsin-Mediated Apoptosis in COPD$408,750
R01 · FY2005 · HL
AMCase and BRP-39 in Th2 Inflammation and Asthma$408,750
R01 · FY2005 · HL
VEGF in Th2 Inflammation and Asthma$408,750
R01 · FY2005 · HL
Mechanisms of IL-13 induced inflammation and fibrosis$298,777
P01 · FY2005 · HL
Initiation and Effector Mechanisms in Lung Th2 Immunity$2,034,302
P01 · FY2004 · HL
VEGF in Th2 Inflammation and Asthma$408,750
R01 · FY2004 · HL
Transgenic Modeling of TGF-Beta in the Lung$408,750
R01 · FY2004 · HL
Initiation and Effector Mechanisms in Lung Th2 Immunity$1,979,642
P01 · FY2003 · HL
RESPIRATORY CELL &MOLECULAR PHYSIOLOGY &BIOLOGY$414,773
T32 · FY2003 · HL
TRANSGENIC MODELING OF COPD$367,875
R01 · FY2003 · HL
Initiation and Effector Mechanisms in Lung Th2 Immunity$1,961,666
P01 · FY2002 · HL
RESPIRATORY CELL &MOLECULAR PHYSIOLOGY &BIOLOGY$413,282
T32 · FY2002 · HL
TRANSGENIC INVESTIGATIONS OF AIRWAY REMODELING$367,875
R01 · FY2002 · HL
TRANSGENIC MODELING OF COPD$367,875
R01 · FY2002 · HL
Mechanisms of IL-13 induced inflammation and fibrosis$280,238
P01 · FY2002 · HL
T LYMPHOCYTES AND CYTOKINES IN ASTHMA$2,000,168
P50 · FY2001 · HL
RESPIRATORY CELL &MOLECULAR PHYSIOLOGY &BIOLOGY$429,043
T32 · FY2001 · HL
TRANSGENIC MODELING OF COPD$367,875
R01 · FY2001 · HL
TRANSGENIC INVESTIGATIONS OF AIRWAY REMODELING$367,875
R01 · FY2001 · HL
TRANSGENIC MODELING OF TH1/TH2 RESPONSES IN ASTHMA$367,875
R01 · FY2001 · HL
TRANSGENIC MODELING OF AIRWAY INFLAMMATION IN ASTHMA$165,355
P50 · FY2001 · HL
INTERLEUKIN 11 IN VIRAL ASTHMA$165,355
P50 · FY2001 · HL
T LYMPHOCYTES AND CYTOKINES IN ASTHMA$1,974,955
P50 · FY2000 · HL
RESPIRATORY CELL &MOLECULAR PHYSIOLOGY &BIOLOGY$402,570
T32 · FY2000 · HL
TRANSGENIC INVESTIGATIONS OF AIRWAY REMODELING$367,875
R01 · FY2000 · HL
TRANSGENIC MODELING OF TH1/TH2 RESPONSES IN ASTHMA$367,875
R01 · FY2000 · HL
TRANSGENIC MODELING OF COPD$361,525
R01 · FY2000 · HL
TRANSGENIC MODELING OF AIRWAY INFLAMMATION IN ASTHMA$186,979
P50 · FY2000 · HL
INTERLEUKIN 11 IN VIRAL ASTHMA$186,979
P50 · FY2000 · HL
INTERLEUKIN 11 IN VIRAL ASTHMA$96,056
R01 · FY2000 · HL